CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Anti-CD19 CAR T-Cell Therapy Induces Significant Remission Rates in B-Cell ALL

September 19th 2016

Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.

New Agents Vie for Role in Multiple Myeloma

September 15th 2016

Despite multiple therapeutic advances in recent years, proteasome inhibitors remain a cornerstone of therapy for multiple myeloma, both newly diagnosed and relapsed and refractory disease.

CAR T-Cell Therapy Continues to Show Promise in Non-Hodgkin Lymphoma

September 13th 2016

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016

Sequencing Monoclonal Antibodies in Myeloma

July 27th 2016

Moving Beyond Medians

July 27th 2016

Novel Agents with Len-Dex in Multiple Myeloma

July 27th 2016

Goals of Therapy for Relapsed Myeloma

July 27th 2016

Treatment Goals Based on Relapse Type in Myeloma

July 27th 2016

All Myeloma Relapses Are Not the Same

July 27th 2016

Efficacy and Safety of Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Immunotherapy Rationale in Multiple Myeloma

July 27th 2016

Dr. Stephanie Goff on Low-Dose Chemotherapy with CAR T-Cells in Advanced Lymphoma

July 27th 2016

CAR T-Cell Therapy CTL019 Shows Promise in Phase II CLL Trial

July 22nd 2016

The CD19-targeting CAR T-cell therapy CTL019 induced responses in 53% of patients with relapsed/refractory chronic lymphocytic leukemia, including complete remissions in 35% of patients.

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

June 10th 2016

CAR Therapy Achieves Durable Responses in Refractory Lymphoma

June 8th 2016

Three-fourths of patients with advanced lymphoma achieved durable objective responses to treatment with chimeric antigen receptor T-cell therapy targeting CD19 even after a low-dose chemotherapy conditioning regimen.

CAR T-cells Rapidly Evolving as Cancer Therapies

March 20th 2016

Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic antiâ€“CD19 chimeric antigen receptorâ€“modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.